share_log

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 10,000 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 10,000 Shares

第一天生物制药公司（纳斯达克股票代码：DAWN）内幕人士塞缪尔·布莱克曼出售了10,000股股票
Defense World ·  2023/01/12 06:21

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, January 10th. The stock was sold at an average price of $22.86, for a total value of $228,600.00. Following the completion of the transaction, the insider now directly owns 1,250,148 shares in the company, valued at $28,578,383.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

第一天生物制药公司(纳斯达克代码：曙光评级)内部人士塞缪尔·C·布莱克曼在1月10日星期二的一笔交易中出售了10,000股第一天生物制药公司的股票。这只股票的平均售价为22.86美元，总价值为228,600.00美元。交易完成后，该内部人士现在直接拥有该公司1,250,148股，价值28,578,383.28美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可以通过美国证券交易委员会网站.

Day One Biopharmaceuticals Stock Up 0.7 %

首日生物制药类股上涨0.7%

Shares of DAWN stock opened at $22.98 on Thursday. The stock's fifty day simple moving average is $20.80 and its 200 day simple moving average is $20.83. Day One Biopharmaceuticals, Inc. has a one year low of $5.44 and a one year high of $28.35.

周四，曙光股票的开盘价为22.98美元。该股的50日简单移动均线为20.80美元，200日简单移动均线为20.83美元。第一天生物制药公司的股价为一年低点5.44美元和一年高点28.35美元。

Get
到达
Day One Biopharmaceuticals
生物制药的第一天
alerts:
警报：

Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) last posted its quarterly earnings data on Monday, November 7th. The company reported ($0.53) EPS for the quarter, hitting analysts' consensus estimates of ($0.53). Equities research analysts expect that Day One Biopharmaceuticals, Inc. will post -2.18 EPS for the current fiscal year.

第一天生物制药(纳斯达克：曙光评级)最近一次公布季度收益数据是在11月7日(星期一)。该公司公布了该季度每股收益(0.53美元)，超过了分析师普遍预期的(0.53美元)。股票研究分析师预计，第一天生物制药公司本财年每股收益将达到2.18美元。

Hedge Funds Weigh In On Day One Biopharmaceuticals

对冲基金在生物制药上市首日发表意见

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Atlas Venture Life Science Advisors LLC boosted its stake in Day One Biopharmaceuticals by 9.3% in the second quarter. Atlas Venture Life Science Advisors LLC now owns 8,968,305 shares of the company's stock worth $160,533,000 after purchasing an additional 766,667 shares in the last quarter. FMR LLC boosted its stake in Day One Biopharmaceuticals by 163.1% in the second quarter. FMR LLC now owns 6,826,574 shares of the company's stock worth $122,196,000 after purchasing an additional 4,232,055 shares in the last quarter. RA Capital Management L.P. boosted its stake in Day One Biopharmaceuticals by 22.0% in the first quarter. RA Capital Management L.P. now owns 6,060,090 shares of the company's stock worth $60,116,000 after purchasing an additional 1,094,502 shares in the last quarter. Deerfield Management Company L.P. Series C boosted its stake in Day One Biopharmaceuticals by 68.3% in the second quarter. Deerfield Management Company L.P. Series C now owns 3,512,123 shares of the company's stock worth $62,867,000 after purchasing an additional 1,425,674 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in Day One Biopharmaceuticals by 29.5% in the third quarter. BlackRock Inc. now owns 2,541,235 shares of the company's stock worth $50,901,000 after purchasing an additional 578,511 shares in the last quarter. Institutional investors and hedge funds own 86.08% of the company's stock.
一些机构投资者和对冲基金最近买卖了该公司的股票。今年第二季度，Atlas Venture Life Science Advisors LLC将其在Day One BiopPharmticals的持股比例提高了9.3%。Atlas Venture Life Science Advisors LLC在上个季度又购买了766,667股后，现在拥有8,968,305股该公司股票，价值160,533,000美元。FMR LLC在第二季度将其在Day One BiopPharmticals的持股增加了163.1%。FMR LLC在上个季度额外购买了4,232,055股后，现在拥有6,826,574股该公司股票，价值122,196,000美元。Ra Capital Management L.P.在第一季度将其在Day One BiopPharmticals的持股增加了22.0%。Ra Capital Management L.P.在上个季度额外购买了1,094,502股后，现在拥有6,060,090股该公司股票，价值60,116,000美元。Deerfield Management Company L.P.Series C在第二季度将其在Day One BiopPharmticals的持股增加了68.3%。Deerfield Management Company L.P.C系列现在拥有该公司3,512,123股股票，价值62,867,000美元，上个季度又购买了1,425,674股。最后，贝莱德股份有限公司在第三季度将其在第一生物制药公司的持股比例提高了29.5%。贝莱德股份有限公司在上个季度增持了578,511股后，目前持有该公司2,541,235股股票，价值50,901,000美元。机构投资者和对冲基金持有该公司86.08%的股票。

Wall Street Analyst Weigh In

华尔街分析师也加入进来

DAWN has been the topic of a number of research reports. Piper Sandler boosted their price objective on Day One Biopharmaceuticals from $40.00 to $45.00 and gave the company an "overweight" rating in a research report on Sunday. Bank of America initiated coverage on Day One Biopharmaceuticals in a research report on Thursday, December 1st. They set a "buy" rating and a $34.00 price objective on the stock. Needham & Company LLC initiated coverage on Day One Biopharmaceuticals in a research report on Wednesday, December 14th. They set a "buy" rating and a $40.00 price objective on the stock. HC Wainwright boosted their price objective on Day One Biopharmaceuticals from $35.00 to $45.00 and gave the company a "buy" rating in a research report on Monday. Finally, The Goldman Sachs Group boosted their price objective on Day One Biopharmaceuticals from $45.00 to $62.00 and gave the company a "buy" rating in a research report on Monday. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of "Buy" and an average target price of $43.50.

黎明已经成为许多研究报告的主题。派珀·桑德勒在周日的一份研究报告中将第一天生物制药公司的目标价从40.00美元上调至45.00美元，并给予该公司“增持”评级。美国银行在12月1日星期四的一份研究报告中开始了对第一天生物制药的保险。他们为该股设定了“买入”评级和34.00美元的目标价。Needham&Company LLC在12月14日星期三的一份研究报告中开始在第一天承保生物制药。他们为该股设定了“买入”评级和40.00美元的目标价。周一，HC Wainwright在一份研究报告中将其在第一天生物制药的目标价从35.00美元上调至45.00美元，并给予该公司“买入”评级。最后，高盛夫妇将第一天生物制药的目标价从45美元上调至62美元，并在周一的一份研究报告中给出了该公司“买入”的评级。根据MarketBeat的数据，六位分析师对该股的评级为买入，第一天生物制药公司目前的共识评级为买入，平均目标价为43.50美元。

About Day One Biopharmaceuticals

关于第一天的生物制药

(Get Rating)

(获取评级)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

第一天生物制药公司是一家临床阶段的生物制药公司，为基因定义的癌症患者开发和商业化靶向疗法。它的主要候选产品是DAY101，这是一种口服II型泛快速加速纤维肉瘤激酶抑制剂，目前正处于儿童复发/进展性低级别胶质瘤患者的II期临床试验中。

Featured Articles

专题文章

  • Get a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)
  • Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
  • Why Hershey Is a Sweet Recession Stock
  • Will Amazon Stock Be Delivering for Investors in 2023?
  • The Analysts Shift Trucking Sentiment Back into Forward
  • The Institutions Book A Flight With Boeing
  • 在第一天生物制药(黎明)获得一份免费的StockNews.com研究报告
  • Bloom Energy在升级后启动，值得冒这个险吗？
  • 好时为什么是一只甜蜜的衰退股票
  • 亚马逊股票是否会在2023年为投资者提供服务？
  • 分析师将货运情绪转回远期
  • 各机构预订波音航班

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

接受《生物制药日报》第一天的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对第一天生物制药和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发